Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.
• Diagnosis and typing of ATTR-CM by endomyocardial biopsy or by Grade 2 or Grade 3 pyrophosphate (PYP) positivity (exception: nonamyloid control arm in aim 1).
‣ Diagnosis of heart failure, with prior or current need of diuretics and increased N-terminal prohormone B-natureitic peptide (BNP) (≥450 pg/ml).
⁃ Peak VO2 \<80% predicted, indicating impaired aerobic capacity (for aim 2 only).
⁃ Taking tafamidis (for aim 2 only)
⁃ Able to walk 4 meters (with or without the use of an assistive device) and independent with basic activities of daily living at the time of enrolment.
⁃ Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention.
⁃ Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.